AMLN Amylin Pharmaceuticals, Inc. (MM)

Amylin Pharmaceuticals Announces Presentation of 12 Abstracts at the American Diabetes Association Annual Meeting Data Disclosure through Company-Sponsored Webcast SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) today announced that data featuring its two recently approved diabetes drugs, BYETTA(TM) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection, will be presented at the 65th Annual Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, California from June 10 - 14, 2005. The meeting is one of the largest for endocrinologists and other health care professionals involved in diabetes research and the delivery of diabetes care. Abstracts for the event can be found on the ADA's website at http://scientificsessions.diabetes.org/. Additionally, the company will be conducting a webcast for investors during the meeting. Amylin has provided an educational grant to support a symposium entitled, "Insulin and Amylin: Balancing Pancreatic Hormones to Achieve Glucose Homeostasis." Presentations will be given by Dr. Stephen Aronoff, Clinical Associate Professor of Medicine, University of Texas Southwest Medical School at Dallas, Dr. John Buse, Chief, Division of General Medicine and Clinical Epidemiology and Director, Diabetes Care Center, University of North Carolina School of Medicine, Dr. Steven Edelman, Professor of Medicine at the University of California San Diego and Ms. Davida Kruger, Certified Nurse Practitioner, Henry Ford Health System. The symposium will be held on Monday, June 13th from 5:30 AM to 7:45 AM Pacific Time. Amylin and Eli Lilly and Company have provided an educational grant to support a symposium entitled, "Engaging the Gears of GLP-1: Incretin Hormones in the Treatment of Type 2 Diabetes." Presentations will be given by Dr. Lawrence Blonde, Director, Ochsner Diabetes Clinical Research Unit, and Associate Director, Department of Internal Medicine, Ochsner Clinic Foundation, Dr. Daniel Drucker, Director, Banting and Best Diabetes Centre, University of Toronto, Toronto General Hospital, Dr. Robert Henry, Professor of Medicine and Chief, VA Endocrinology and Metabolism, University of California San Diego and Deborah Hinnen, Practice Development Specialist, Diabetes, Via Christi-Prevention and Health, Diabetes Management at Genesis. The symposium will be held on Sunday, June 12th from 5:30 AM to 7:45 AM Pacific Time. Amylin will be conducting a webcast for investors on Sunday, June 12, 2005 at 6:30 PM Pacific Time to review the information presented at the ADA and provide an update on BYETTA and SYMLIN commercial activities. The live presentation will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com/. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software. ABSTRACTS BEING PRESENTED AT THE ADA: 1. Comparison of Exenatide and Insulin Glargine in MET and SU-Treated Patients With Type 2 Diabetes: Exenatide Achieved Equivalent Glycemic Control, With Weight Reduction and Less Nocturnal Hypoglycemia; R. Heine (Oral presentation) 2. Improvements in Cardiovascular Risk Factors Accompanied Sustained Effects on Glycemia and Weight Reduction in Patients With Type 2 Diabetes Treated With Exenatide for 82 Weeks; D. Kendall (Oral presentation) 3. Exenatide Pharmacokinetics in Patients With Mild to Moderate Renal Dysfunction and End Stage Renal Disease; H. Linnebjerg (Poster) 4. Exenatide (Exendin-4) Reduced A1C and Weight Over 82 Weeks in Overweight Patients With Type 2 Diabetes; L. Blonde (Poster) 5. Mathematical Modeling Shows Exenatide Improved Postprandial Beta-Cell Function in Patients With Type 2 Diabetes Treated With Metformin or Metformin and Sulfonylurea; A. Mari (Poster) 6. Exenatide-Induced Reductions in A1C and Body Weight in Long-Term Trials Are Not Explained by Gastrointestinal Side Effects; D. Maggs (Poster) 7. Insulinotropic Action of Exenatide (Exendin-4) Abates During Hypoglycemia in Rats; D. Parkes (Poster) 8. In an Open-Label Clinical Study Pramlintide Lowered A1C, Body Weight, and Insulin Use in Patients With Type 2 Diabetes Failing to Achieve Glycemic Targets With Insulin Therapy; D. Karl (Oral presentation) 9. In an Open-Label Clinical Study Pramlintide Lowered A1C, Body Weight, and Insulin Use in Patients With Type 1 Diabetes Failing to Achieve Glycemic Targets With Insulin Therapy; R. Guthrie (Poster) 10. Perceptions of Patient Satisfaction During the Placebo-Controlled and Open-Label Phases of a Study in Patients With Type 1 Diabetes Treated With Pramlintide; D. Marrero (Publication only) 11. Effect of the Beta-cell Hormone Amylin on Food Intake, Body Weight, Body Composition and Metabolic Indicators in High Fat-Fed Rats Following Cessation of Treatment; C. Mack (Oral presentation) 12. Effect of the Beta-cell Hormone Amylin on Food Intake, Body Weight and Body Composition in High Fat-Fed Mice Upon Continuous vs. Intermittent Treatment; C. Jodka (Poster) About Amylin Pharmaceuticals Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Further information on Amylin and its pipeline in metabolism is available at http://www.amylin.com/ . Safe Harbor/Forward Looking Statements This press release contains forward-looking statements about Amylin. The company's actual results could differ materially from those discussed in this press release due to a number of risks and uncertainties, including that BYETTA and/or SYMLIN may not prove to be important new therapeutic options or may be affected by unexpected new data or technical issues, or that the Company may not be able to effectively launch BYETTA and/or SYMLIN. Commercial and government reimbursement and pricing decisions, the pace of market acceptance and any issues related to manufacturing and supply may also affect the potential for BYETTA and/or SYMLIN. These and additional risks and uncertainties are described more fully in the Company's recently filed Form 10-K. Amylin undertakes no duty to update these forward-looking statements. DATASOURCE: Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner, Executive Director, Investor Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200 ext. 7272 Web site: http://www.amylin.com/ http://scientificsessions.diabetes.org/

Copyright